Methods and compositions for treating chronic myelomonocytic leukemia (cmml)

In the present invention, inventors have used high throughput sequencing to identify novel mutations in ABCA1 in CMML patient samples. Further studies in a mouse model of myelomonocytic leukemia driven by hematopoietic Tet2 deficiency have shown that these 10 somatic mutations abrogate the tumor suppressor function of WT ABCA1, resulting in the failure to suppress canonical IL3-receptor beta signaling-driven myelopoiesis. The loss of the myelo-suppressive function of ABCA1 mutants can be overcome by raising HDL levels through overexpression of the human apolipoprotein A-1 (apoA-1) transgene. Inventors have also shown that both IL-3Rbeta blocking antibody and cyclodextrin prevented the 15 proliferation of ABCA1 mutant-transduced Tet2 deficient BM cells similar to the effect of ABCA1-WT overexpression. Accordingly, the invention relates to a method for predicting the survival time of a subject suffering from CMML comprising the step identifying at least one ABCA1 and to a method for treating said subject with HDL/ABCA recombinant (ApoA-1); cylodextrin and/or anti-IL-3Rbeta antibody.

Keywords: ABCA1, mutation, CMML, Oncology - Haematology, IL3R beta blocking antibody and cyclodextrin treatment
Patent Application number: EP 19306501.8
Publications:
Cell Rep. 2020 Mar 10 Viaud et al. ABCA1 Exerts Tumor-Suppressor Function in Myeloproliferative Neoplasms DOI: 10.1016/j.celrep.2020.02.056

You might also be interested in